Related Experiment Video
Updated: Nov 15, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins for treatment of chronic liver disease
Mohamad Kareem Marrache1, Don C Rockey
1Digestive Disease Research Center, Medical University of South Carolina, Charleston, South Carolina, USA.
Insights
Statins, used for cardiovascular disease, are increasingly found to be safe and beneficial for patients with chronic liver disease (CLD). Research indicates potential benefits in reducing complications and improving survival in CLD patients.
Area of Science:
- Hepatology
- Pharmacology
- Cardiovascular Medicine
Background:
- Statins are lipid-lowering medications traditionally contraindicated in patients with liver disease.
- Recent evidence challenges the notion of statin harm in chronic liver disease (CLD).
Purpose of the Study:
- To review the latest literature on statin mechanisms, safety, and benefits in CLD.
- To discuss the impact of statins on CLD progression and complications.
Main Methods:
- Review of recent literature on statin use in various forms of CLD.
- Analysis of studies examining safety profiles and clinical outcomes.
Main Results:
- Statins demonstrate safety and potential benefits in patients with CLD, including viral hepatitis and nonalcoholic fatty liver disease.
- Studies show lower rates of decompensation, hepatocellular cancer, infections, and improved survival in CLD patients on statins.
- Evidence suggests statins may reduce fibrosis, even in advanced stages of liver disease.
Conclusions:
- Statins appear safe for patients with compensated cirrhosis and may offer antifibrotic effects.
- Further high-quality research is necessary to fully establish the role of statins in managing CLD.
Purpose Of Review:
Statins are a class of lipid lower medications used primarily in patients with high-risk cardiovascular disease. Since their development, statins have been considered to be harmful in patients with liver disease, and many of the prescribing information labels consider them to be contraindicated in patients with active liver disease. However, recent studies have shown the contrary, warranting further investigation and discussion. This review aims to describe the latest literature on the mechanism, safety profile and potential benefits of statins use on the natural history of chronic liver disease (CLD) progression and its complications.
Recent Findings:
A number of recently published studies have added to the existing body of literature supporting the concept that statins are safe and likely to be beneficial for treating patients with CLD. Patients with CLD including hepatitis B virus infection, hepatitis C virus infection, nonalcoholic fatty liver disease and alcohol on statins have been shown to have a lower rate of decompensating events, lower incidence of hepatocellular cancer, a lower rate of infections, and increased survival. However, the majority of the available literature supporting statin use in patients with liver disease comes from retrospective observational studies with high potential for bias.
Summary:
Statins appear to be safe in patients with compensated cirrhosis, and evidence suggests that they may reduce fibrosis, even in patients with advanced fibrosis and cirrhosis. Further high-quality research on this topic is needed to fully delineate the effect of statins in patients with liver disease.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

